Neurologic Manifestations of Hypoglycemia
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Tactics of Family Doctors in Case of Syncopal States
MINISTRY OF PUBLIC HEALTH OF UKRAINE ZAPORIZHZHIA STATE MEDICAL UNIVERSITY DEPARTMENT OF GENERAL PRACTICE – FAMILY MEDICINE AND INTERNAL DISEASES DEPARTMENT OF GENERAL PRACTICE – FAMILY MEDICINE, THERAPY, CARDIOLOGY AND NEUROLOGY OF THE POSTGRADUATE FACULTY TACTICS OF FAMILY DOCTORS IN CASE OF SYNCOPAL STATES STUDY GUIDE for the students of the specialty "Medicine" in the program of the educational discipline "General Practice - Family Medicine" Zaporizhzhia 2020 2 UDC 616.8-009.832-08(072) М 99 Аpproved by Central Methodical Council of Zaporizhzhia State Medical University as а study guide (Protocol № 3 of 27.02.2020) and recommended for use in the educational process Authors: N. S. Mykhailovska - Doctor of Medical Sciences, Professor, head of the Department of General practice – family medicine and internal diseases, Zaporizhzhia State Medical University; A. V. Grytsay - PhD, associated professor of the Department of General practice – family medicine and internal diseases, Zaporizhzhia State Medical University; І. S. Kachan - associated professor of the Department of Family medicine, therapy, cardiology and neurology of the Postgraduate faculty, Zaporizhzhia State Medical University. Readers: S. Y. Dotsenko – Doctor of Medical Sciences, Professor, Head of the Internal Medicine №3 Department, Zaporozhye State Medical University; S. M. Kiselev – Doctor of Medical Sciences, Professor, Professor of the Department of Internal diseases 1, Zaporizhzhia State Medical University. Mykhailovska N. S. M99 Tactics of family doctors in case of syncopal states = Тактика сімейного лікаря при синкопальних станах: study guide for the practical classes and individual work for 6th-years students of international faculty (speciality «General medicine»), discipline «General practice – family medicine» / N. S. Mykhailovska, A. V. Grytsay, I.S. -
Reactive Hypoglycemia from Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves
Open Access Case Report DOI: 10.7759/cureus.16112 Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves Ayesha Akram 1, 2 1. Internal Medicine, Combined Military Hospital, Rawalpindi, PAK 2. Internal Medicine, Rawalpindi Medical University, Rawalpindi, PAK Corresponding author: Ayesha Akram, [email protected] Abstract Metformin rarely, if ever, causes hypoglycemia when it is used as labeled. A 55-year-old woman presented to the medicine ward with an altered level of consciousness. She had been reviewed in an outpatient department three days earlier and prescribed 500 mg two times per day of metformin immediate-release (Met IR) for newly diagnosed type 2 diabetes mellitus (T2DM), to which she had been adherent; however, she had been experiencing intermittent episodes of hypoglycemia after taking the medication prescribed to treat her T2DM. On physical examination, she was diaphoretic and disoriented but responsive to sensory stimuli. In the ward, she received 25 ml of intravenous dextrose as the initial blood glucose reading was low at 54 mg/dl, and 4 ounces of apple juice additionally two hours later as her blood glucose level fell below 70 mg/dl again. She was no longer hypoglycemic a few hours later, and there was a significant neurological improvement. The remainder of the laboratory results, including serum renal and liver function tests, were normal. Met IR was discontinued, and metformin extended-release (Met XR) 500 mg/day was initiated at discharge. The patient's hypoglycemic episodes resolved within days after the initiation of Met XR. -
Table of Contents
DISCLAIMER The information contained within this document is restricted to and intended for professional use by licensed health care providers. The statements made should not be construed as a claim, nor does it represent any particular product procedure or advice as constituting a specific cure, whether palliative or ameliorative. Procedures and products mentioned are designed to support the client’s health and may be considered as support for other procedures deemed necessary by the practitioner. Although specific manufacturers make the supplements, herbs and homeopathies referenced in this document, the opinions expressed are those of the author and are not those of any of the manufacturers. This document is not designed to replace medical advice or medical treatments, but to be used adjunctively in the care and support of health and vitality. 9 © Copyright 2005 Return to Table of Contents . CHAPTER II: SUGAR HANDLING BLOOD SUGAR STABILIZATION RELATED CONDITIONS • Hypoglycemia PROTOCOL AT A GLANCE • Reactive Hypoglycemia • Low blood sugar Primary Supplemental Support • Syndrome X Bio-Glycozyme Forte • Triglycerides high Biomega-3 • Carbohydrate sensitivity Secondary Supplemental Support • Pre-diabetic Whey Protein Isolate • B vitamin deficiency Amino Acid Quick Sorb • Sugar sensitivity Beta-TCP • Food cravings ADHS Cytozyme-PAN • Carbohydrate cravings Cytozyme-LV Cytozyme-AD PHYSIOLOGIC CONSIDERATIONS Tri-Chol Blood sugar problems begin in childhood with excess use of sugary snacks and drinks. This is extremely common today. The U.S. Department of Agriculture estimates that the average American consumes from 150 to 180 pounds of sugar each year––an unbelievable amount compared to two or three hundred years ago when normal sugar consumption was one to five pounds per year. -
Unarousable Unresponsiveness in Which the Patient Lies with the Eye Closed and Has No Awareness of Self and Surroundings (2)
Neurological Disease Deborah M Stein, MD, MPH 1. Coma a. Coma is defined as “a state of extreme unresponsiveness, in which an individual exhibits no voluntary movement or behavior” (1). i. Alternatively, coma is a state of unarousable unresponsiveness in which the patient lies with the eye closed and has no awareness of self and surroundings (2). b. Coma lies on a spectrum with other alterations in consciousness – from confusion to delirium to obtundation to stupor to coma and, ultimately, brain death (2). c. To be clearly distinguished from syncope, concussion, or other states of transient unconsciousness coma must persist for at least one hour (2). d. There are 2 important characteristics of the conscious state (3) i. The level of consciousness – “arousal or wakefulness” 1. Regulated by physiological functioning and consists of more primitive responsiveness to the world such as predictable involuntary reflex responses to stimuli. 2. Arousal is maintained by the reticular activating system (RAS) - a network of structures (including the brainstem, the medulla, and the thalamus) ii. The content of consciousness – “awareness” 1. Regulated by cortical areas within the cerebral hemispheres, e. There are two main causes for coma: i. Bihemispheric diffuse cortical or white matter damage or ii. Brainstem lesions bilaterally affecting the subcortical reticular activating systems. f. A huge number of conditions can result in coma. One way to categorize these conditions is to divide them into the anatomic and the metabolic causes of coma. i. Anatomic causes of coma are those conditions that disrupt the normal physical architecture and anatomy, either at the level of the cerebral cortex or the brainstem ii. -
Heat Illness & Hydration
Sideline Emergencies: Exertional Heat Illness- Prevention and Treatment Updates AOSSM: 2019 Sports Medicine & Football - Youth to the NFL Damion A. Martins, MD Medical Director of Sports Medicine Sports Medicine Fellowship Program Director, Atlantic Health Systems Director of Internal Medicine, New York Jets DISCLOSURE Neither I, (Damion Martins, MD), nor any family member(s), author(s), have any relevant financial relationships to be discussed, directly or indirectly, referred to or illustrated with or without recognition within the presentation. Learning Objectives Describe the pathophysiology of Exertional Heat Illness Identify signs and symptoms of Exertional Heat Stroke Understand urgent on the field management and treatment of Heat Illness Understand current evidence for prevention and treatment of Exertional Heat Stroke Overview Heat Illness – Diagnosis – Pathophysiology – Risk Factors – Evaluation / Treatment Hydration – NCAA / NFL data – IV vs PO data McNair video 6 Physiology Thermoregulation Production Dissipation – – basal metabolism conduction – – exercise radiation – convection – evaporation Sandor RP. Phys SportsMed. 1997;25(6):35-40. Heat Illness Spectrum Heat Illness Heat Injury Heat Stroke Definitions Exertional Heat Illness (EHI) Heat edema – initial days of heat exposure – self-limited, mild swelling of hands / feet Heat cramps or Exercise Associated Muscle Cramps (EAMCs) – skeletal muscle cramping during or after exercise – usually abdominal and extremities Heat syncope – orthostatic dizziness or sudden -
1 Jasvinder Chawla, MD, MBA Chief Neurology, Hines Veterans Affairs
Jasvinder Chawla, MD, MBA Chief Neurology, Hines Veterans Affairs Hospital, Professor of Neurology, Loyola University Medical Medical Center Jasvinder Chawla, MD, MBA is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Clinical Neurophysiology Society, American Medical Association. Specialty Editor Board Francisco Talavera, PharmD, PhD Adjuct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Editor-in-Chief, Medscape Drug Reference Howard S Kirshner, MD Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine, Director, Vanderbilt Stroke Center, Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital, Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center. Chief Editor Helmi L Letsep, MD Professor and Vice Chair, Department of Neurology, Oregon Health and Science University School of Medicine, Associate Director, OHSU Stoke Center Additional Contributors Pitchaiah Mandava, MD, PhD Assistant Professor, Department of Neurology, Baylor College of Medicine, Consulting Staff, Department of Neurology, Michael E DeBakey Veterans Affairs Medical Center. Richard M Zweifler, MD Chief of Neurosciences, Sentara Healthcare, Professor and Chair of Neurology, Eastern Virginia Medical School. 1 Thomas A Kent, MD Professor and Director of Stroke Research and Education, Department -
Public Comment 8
www.JazzPharmaceuticals.com May 20, 2021 Priya Shah West Virginia Medicaid 350 Capitol Street, Room 251 Charleston WV 25301 Dear Priya Shah, Thank you for your request for information regarding XYWAV™ (calcium, magnesium, potassium, and sodium oxybates) oral solution. If you did not specifically request the enclosed information, please contact Jazz Medical Information at 1-800-520-5568. XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. Below is the information you requested. • XYWAV (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Written Comments for Medicaid • XYWAV Prescribing Information Please refer to the accompanying XYWAV™ full Prescribing Information including the Boxed Warning. This information is provided to you as a professional courtesy and may include content that has not been approved by the United States Food and Drug Administration (FDA). Statements in this communication are not intended to advocate any indication, dosage, or other claim not set forth in the prescribing information. This response contains information of a general nature and is intended solely to assist you in formulating your own conclusions regarding our product. It is not meant to be a thorough review of the literature and does not represent all professional points of view on this subject. Thank you for your interest in XYWAV™. Please contact Medical Information at 1-800-520-5568 if you have further questions. Sincerely, Jazz Pharmaceuticals -
Blood Sugar the Hidden Factor in Health
Blood Sugar The Hidden Factor in Health Disorders in blood sugar balance disrupt all aspects of human physiology. To understand this, we must keep in mind that our bodies primarily produce their energy from converting glucose (blood sugar) into ATP. If this system is not working properly, health cannot be achieved. Blood sugar disorders are extraordinarily common in the U.S. today. Much (but not all) of the prob- lem can be placed on the Standard American Diet that is high in saturated fats and sugars while being low in essential fatty acids and fiber. In the past decade, there has been an explosion in the number of cases of diabetes, which only figures to grow in the decades ahead. Insulin Insulin is a protein hormone secreted by the pancreas. Its primary job is to stimulate the uptake of glucose from our blood into our cells. Cell membranes have a lipid layer thru which glucose cannot pass on its own. It has to be carried across with the assistance of insulin. Once inside the cells, glu- cose can be used for energy. All foods are ultimately converted into glucose. An increase of glucose in the bloodstream stimulates the release of more insulin. Insulin promotes the production of glycogen, which is the form that glucose is stored in, for later use. Insulin also promotes the formation of lipids, triglyceride and protein. Alterations in insulin are responsible for causing metabolic disorders such as hypoglycemia and diabetes. Hypoglycemia If the pancreas overreacts to a sudden surge in glucose, it will release excess insulin which will subsequently cause a drop in blood sugar. -
Postconcussional Disorder and Loss of Consciousness
Postconcussional Disorder and Loss of Consciousness Stephen D. Anderson, MD, FRCP(C) Postconcussional disorder (PCD) has been described in the psychiatric, neuro- logical, neuropsychological, and rehabilitation medicine literature for many years. PCD has recently been introduced into DSM-IV, appearing in an appendix that contains a number of proposals for new categories and axes that were suggested for possible inclusion in DSM-IV. There are some major difficulties with the proposed criteria for PCD. This article explores some of these difficulties, partic- ularly focusing on the criteria of loss of consciousness (LOC). A review of the literature demonstrates that LOC is not necessary for PCD to occur. The major difficulty with the DSM-IV criteria is the definition of concussion. The article suggests that, instead, the criteria for mild traumatic brain injury, as defined by the American Congress of Rehabilitation Medicine, may be more appropriate. Postconcussional disorder (PCD) has been symptoms include headache pain, nausea. described in the medical literature for dizziness or vertigo. unsteadiness or poor over a century. The telm Post-concussion coordination, tinnitus, hearing loss. blurred syndrome was coined by Strauss and vision, diplopia, convergence insufficiency. Savitsky in 1934.' PCD is the most preva- light and noise sensitivity, and altered sense lent and yet controversial neuropsychiat~ic of taste and smell. The cognitive deficits diagnosis following brain injury. PCD is include memory difticulties, decreased at- linked most commonly to minor brain in- tention and concentration, decreased speed jury. because the symptoms are unobscured of information processing, communication by the myriad of findings that accompany a difficulties, difficulties with executive fin- more severe brain injuly. -
Xyrem (Sodium Oxybate) Is a CNS Depressant
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Important Administration Information for All Patients XYREM safely and effectively. See full prescribing information for • Take each dose while in bed and lie down after dosing (2.3). XYREM. • Allow 2 hours after eating before dosing (2.3). • Prepare both doses prior to bedtime; dilute each dose with approximately ¼ XYREM® (sodium oxybate) oral solution, CIII cup of water in pharmacy-provided containers (2.3). Initial U.S. Approval: 2002 • Patients with Hepatic Impairment: starting dose is one-half of the original dosage per night, administered orally divided into two doses (2.4). • WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION Concomitant use with Divalproex Sodium: an initial reduction in Xyrem dose and ABUSE AND MISUSE. of at least 20% is recommended (2.5, 7.2). --------------------DOSAGE FORMS AND STRENGTHS------------------- See full prescribing information for complete boxed warning. Oral solution, 0.5 g per mL (3) Central Nervous System Depression ----------------------------CONTRAINDICATIONS------------------------------ • Xyrem is a CNS depressant, and respiratory depression can occur with • In combination with sedative hypnotics or alcohol (4) Xyrem use (5.1, 5.4) • Succinic semialdehyde dehydrogenase deficiency (4) Abuse and Misuse • Xyrem is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, ---------------------WARNINGS AND PRECAUTIONS---------------------- -
Jack L. Snitzer,D.O
JACK L. SNITZER,D.O. Internal Medicine Board Review Course 2019 ENDOCRINE PANCREAS JACK L. SNITZER, D.O. Peninsula Regional Endocrinology 1415 S. Division Street Salisbury, MD 21804 Phone:410-572-8848 Fax:410-572-6890 E-Mail: [email protected] Endocrine Pancreas n Alpha Cells: Glucagon n Beta Cells: Insulin n Delta Cells: Somatostatin n D1 Cells: Vasoactive intestinal Polypeptide (VIP) n F Cells: Pancreatic Polypeptide (PP) n G Cells: Gastrin GLUCAGONOMA -Glucagonoma Causes increased glucose production. Rare, often malignant tumors. Classic Rash: Necrolytic Migratory Erythema Painful glossitis, angular stomatitis. Tx: Surgery, Octreotide INSULINOMA -Insulinoma Spontaneous hypoglycemia. 80% are benign. Usually very small tumors. Second most common pancreatic tumor found in MEN 1. INSULINOMA -Insulinoma Dx: elevated insulin and C-peptide level with simultaneously low glucose and symptoms. -Fasting glucose <50 mg/dl. Tx: Surgery. Octreotide to palliate. Hypoglycemia: other causes in non- diabetics • Reactive hypoglycemia (generally in obese patient with metabolic syndrome) • Malnutrition (celiac disease, eating disorder, etc.) • Cortisol insufficiency (adrenal or pituitary cause) • Nesidioblastosis (for instance: post-gastric bypass: islet cell hyperplasia) Hypoglycemia: other causes in non- diabetics • Liver disease • Surreptitious, malicious or inadvertent use of insulin. In this case, when the BG is low, insulin level will be high and C-peptide level will be low. Need to obtain these levels before treating with glucose or glucagon. • Surreptitious use of insulin secretagogue. Insulin and c- peptide levels will be high when BG is low. • Glucometer error (glucose meters are inaccurate when the BG is low); or hypoperfusion of the fingers Hypoglycemia: other causes in non- diabetics • Remember: early hypoglycemia symptoms (shakes, sweats, anxiety, hunger) are due to catecholamine release. -
Dr. Ritamarie Loscalzo 10Min. Transcript
The Blood Sugar Spectrum & Women’s Health. Clinical training by Dr. Ritamarie Loscalzo and Dr. Jessica Drummond Jessica Drummond: Hi, everyone. It's Jessica Drummond here from the Integrative Women's Health Institute and I am honored to be joined by Dr. Ritamarie Loscalzo. She is essentially an expert in a part of nutrition that she has termed, and I think it's a perfectly a perfect term for this, nutritional endocrinology. She really thinks about hormones from a very root cause perspective for men and women. Today, we're going to be talking about how insulin resistance, blood sugar imbalances impact hormonal health for women and in general. So welcome, Ritamarie. How are you? Dr. Ritamarie L: I'm really good. Thank you, Jessica. I'm excited to be talking to you today and to share this passion of mine. Jessica Drummond: Excellent. So I'll let you dive right in. Ritamarie's got a presentation for us and I may bust in from time to time and ask some questions. Dr. Ritamarie L: Please do. Let's make it fun. All right. So, welcome, everybody, and thank you for your attention. I'm excited to be here and talk to Jessica's group. I know that you guys are really into female health and women's health, and a big part of that obviously is hormones. Dr. Ritamarie L: The first thing that I like to say when I talk about hormones is that hormones is not just about sex. I know we all want to go to the bedroom, we all want to talk about the sex hormones, but there's so many other hormones that play into how those sex hormones function.